Morgan Stanley
WHWK

Morgan Stanley’s Whitehawk Therapeutics WHWK Stock Holding History

Morgan Stanley’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.8K Buy
8,342
+1,594
+24% +$4.99K ﹤0.01% 6600
2025
Q4 		$16.3K Buy
6,748
+4,899
+265% +$11.2K ﹤0.01% 6756
2025
Q3 		$3.51K Sell
1,849
-154
-8% -$283 ﹤0.01% 7176
2025
Q2 		$3.75K Sell
2,003
-62,234
-97% -$108K ﹤0.01% 7106
2025
Q1 		$114K Buy
64,237
+51,476
+403% +$134K ﹤0.01% 5952
2024
Q4 		$40.3K Buy
12,761
+10,350
+429% +$23.4K ﹤0.01% 6356
2024
Q3 		$4.97K Sell
2,411
-62,493
-96% -$101K ﹤0.01% 6921
2024
Q2 		$94.8K Sell
64,904
-399,562
-86% -$740K ﹤0.01% 5983
2024
Q1 		$1.09M Sell
464,466
-556,876
-55% -$1.07M ﹤0.01% 4910
2023
Q4 		$2.06M Buy
1,021,342
+802,199
+366% +$3.37M ﹤0.01% 4905
2023
Q3 		$1.06M Buy
219,143
+121,434
+124% +$706K ﹤0.01% 4767
2023
Q2 		$668K Buy
97,709
+79,850
+447% +$621K ﹤0.01% 5066
2023
Q1 		$129K Buy
17,859
+15,165
+563% +$162K ﹤0.01% 5907
2022
Q4 		$34.6K Sell
2,694
-6,313
-70% -$82.4K ﹤0.01% 6449
2022
Q3 		$127K Sell
9,007
-14,218
-61% -$187K ﹤0.01% 5959
2022
Q2 		$286K Sell
23,225
-12,593
-35% -$187K ﹤0.01% 5711
2022
Q1 		$608K Buy
35,818
+33,127
+1,231% +$635K ﹤0.01% 5292
2021
Q4 		$65K Buy
2,691
+2,600
+2,857% +$65.3K ﹤0.01% 6680
2021
Q3 		$3K Buy
+91
New +$2.77K ﹤0.01% 7614
2021
Q1 		– Sell
-1,671
Closed -$25K – 7586
2020
Q4 		$25K Buy
+1,671
New +$35.7K ﹤0.01% 6369
2019
Q2 		– Sell
-65
Closed -$1K – 6773
2019
Q1 		$1K Buy
65
+30
+86% +$1.29K ﹤0.01% 6546
2018
Q4 		$1K Sell
35
-176
-83% -$5.6K ﹤0.01% 6532
2018
Q3 		$10K Buy
+211
New +$11.8K ﹤0.01% 6308

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Morgan Stanley's WHWK Position: Q1 2026 in Review

Morgan Stanley increased its Whitehawk Therapeutics (WHWK) stake by 24% in Q1 2026, buying an estimated $4.99K and bringing the position to 8,342 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6600.

Morgan Stanley first reported a position in WHWK in Q3 2018 and has held it in 23 quarters since. The position peaked at $2.06M in Q4 2023. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Morgan Stanley held 8,342 shares of Whitehawk Therapeutics worth $28.8K as of Q1 2026.
  • Morgan Stanley bought 1,594 Whitehawk Therapeutics shares in Q1 2026, an estimated $4.99K.
  • Whitehawk Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6600 holding.
  • Morgan Stanley first reported a position in Whitehawk Therapeutics in Q3 2018 and has held it in 23 quarters since.
  • Morgan Stanley's Whitehawk Therapeutics position peaked at $2.06M in Q4 2023.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.